259 related articles for article (PubMed ID: 35242129)
21. Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.
Nakamae H
Front Immunol; 2024; 15():1403936. PubMed ID: 38903503
[TBL] [Abstract][Full Text] [Related]
22. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
23. Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.
Cuthbertson P; Button A; Sligar C; Elhage A; Vine KL; Watson D; Sluyter R
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339054
[TBL] [Abstract][Full Text] [Related]
24. Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression.
Nakamura M; Meguri Y; Ikegawa S; Kondo T; Sumii Y; Fukumi T; Iwamoto M; Sando Y; Sugiura H; Asada N; Ennishi D; Tomida S; Fukuda-Kawaguchi E; Ishii Y; Maeda Y; Matsuoka KI
Sci Rep; 2021 Jun; 11(1):13125. PubMed ID: 34162921
[TBL] [Abstract][Full Text] [Related]
25. Sigle Agent of Posttransplant Cyclophosphamide Without Calcineurin Inhibitor Controls Severity of Experimental Chronic GVHD.
Saeki K; Fujiwara H; Seike K; Kuroi T; Nishimori H; Tanaka T; Matsuoka KI; Fujii N; Maeda Y
Acta Med Okayama; 2024 Apr; 78(2):123-134. PubMed ID: 38688830
[TBL] [Abstract][Full Text] [Related]
26. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.
Kanakry CG; Ganguly S; Zahurak M; Bolaños-Meade J; Thoburn C; Perkins B; Fuchs EJ; Jones RJ; Hess AD; Luznik L
Sci Transl Med; 2013 Nov; 5(211):211ra157. PubMed ID: 24225944
[TBL] [Abstract][Full Text] [Related]
27. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
28. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation.
Massoud R; Gagelmann N; Fritzsche-Friedland U; Zeck G; Heidenreich S; Wolschke C; Ayuk F; Christopeit M; Kröger N
Haematologica; 2022 Apr; 107(4):857-867. PubMed ID: 33832208
[TBL] [Abstract][Full Text] [Related]
29. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
30. Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide.
Sligar C; Cuthbertson P; Miles NA; Adhikary SR; Elhage A; Zhang G; Alexander SI; Sluyter R; Watson D
Immunol Cell Biol; 2023 Aug; 101(7):639-656. PubMed ID: 37191045
[TBL] [Abstract][Full Text] [Related]
31. PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade.
Ikegawa S; Meguri Y; Kondo T; Sugiura H; Sando Y; Nakamura M; Iwamoto M; Maeda Y; Matsuoka KI
Blood Adv; 2019 Dec; 3(23):4081-4094. PubMed ID: 31821459
[TBL] [Abstract][Full Text] [Related]
32. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant.
Zhao C; Bartock M; Jia B; Shah N; Claxton DF; Wirk B; Rakszawski KL; Nickolich MS; Naik SG; Rybka WB; Ehmann WCC; Hohl RJ; Valentin J; Bernas-Peterson M; Gerber EM; Zimmerman M; Mierski JA; Mineishi S; Zheng H
J Hematol Oncol; 2022 May; 15(1):64. PubMed ID: 35590334
[TBL] [Abstract][Full Text] [Related]
33. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
[TBL] [Abstract][Full Text] [Related]
34. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
35. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide.
Rambaldi B; Kim HT; Reynolds C; Chamling Rai S; Arihara Y; Kubo T; Buon L; Gooptu M; Koreth J; Cutler C; Nikiforow S; Ho VT; Alyea EP; Antin JH; Wu CJ; Soiffer RJ; Ritz J; Romee R
Blood Adv; 2021 Jan; 5(2):352-364. PubMed ID: 33496734
[TBL] [Abstract][Full Text] [Related]
36. [Allogeneic hematopoietic stem cell transplantation using posttransplant cyclophosphamide].
Sugita J
Rinsho Ketsueki; 2020; 61(9):1402-1410. PubMed ID: 33162542
[TBL] [Abstract][Full Text] [Related]
37. Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy.
Leserer S; Graf T; Franke M; Bogdanov R; Arrieta-Bolaños E; Buttkereit U; Leimkühler N; Fleischhauer K; Reinhardt HC; Beelen DW; Turki AT
Front Immunol; 2023; 14():1082727. PubMed ID: 37020562
[TBL] [Abstract][Full Text] [Related]
38. Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight.
McCurdy SR; Luznik L
Blood Rev; 2023 Nov; 62():101093. PubMed ID: 37198064
[TBL] [Abstract][Full Text] [Related]
39. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
[TBL] [Abstract][Full Text] [Related]
40. Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation.
Vela-Ojeda J; Montiel-Cervantes L; Granados-Lara P; Reyes-Maldonado E; García-Latorre E; Garcia-Chavez J; Majluf-Cruz A; Mayani H; Borbolla-Escoboza JR; Esparza MG
Stem Cells Dev; 2010 Mar; 19(3):333-40. PubMed ID: 19919293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
